The subjective effects of MDMA and mCPP in moderate MDMA users

Area of Science:

• Neuroscience
• Psychopharmacology
• Addiction Research

Background:

• Understanding the neurochemical basis of drug abuse liability is crucial.
• 3,4-methylenedioxymethamphetamine (MDMA) and related compounds are frequently studied for their dependence potential.
• Prototypical dopamine (D-amphetamine) and serotonin (mCPP) releasing agents serve as benchmarks.

Purpose of the Study:

• To establish a safe and effective dose range for MDMA and mCPP in human studies.
• To compare the subjective and physiological effects of MDMA and mCPP.
• To investigate the abuse liability of MDMA in relation to dopamine and serotonin releasing agents.

Main Methods:

• A dose-escalation study was conducted with moderate MDMA users.
• Participants received single doses of MDMA (75, 110, 145 mg/70 kg) or mCPP (17.5, 35, 52.5 mg/70 kg) in a controlled laboratory setting.
• Physiological measures (blood pressure, heart rate) and subjective effects (POMS, ARCI, VAS, HRS) were assessed.

Main Results:

• MDMA administration led to significant increases in blood pressure and heart rate.
• Both MDMA and mCPP induced stimulant subjective effects.
• MDMA and mCPP also produced hallucinogenic effects, with mCPP's hallucinogenic effects being a novel finding.
• MDMA increased scores on measures of elation, stimulation, and hallucinogenic perception.

Conclusions:

• The study successfully identified safe and active dose ranges for MDMA and mCPP.
• Both MDMA and mCPP possess stimulant and hallucinogenic properties.
• The findings contribute to understanding the neurochemical mechanisms of MDMA's abuse liability and highlight previously unobserved effects of mCPP.